[Treatment of seronegative myasthenia garvis].
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. It is classified into 1) the nicotinic acetylcholine receptor antibodies (80-85%), 2) muscle- specific tyrosine kinase antibodies (5-10%), and 3) the above-mentioned antibody absent, double seronegative MG. In this symposium, I focused the treatment of double seronegative MG.